Sun Pharma Advanced Research Co Share Price Today | Stock Price & Sun Pharma Advanced Research Co Share Screener
As of October 5, 2026, the live Sun Pharma Advanced Research Co share price (NSE: SPARC) is ₹191.26 on NSE and ₹190.70 on BSE, down 1.48% from the previous close, with shares trading between ₹190.20 and ₹201.59 in today's trading session, and a 52-week range of ₹108.71–₹277.57. Check SPARC yearly price range for the annual price range and momentum. Use the Sun Pharma Advanced Research Co stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sun Pharma Advanced Research Co opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹15 and net income of ₹1,761, with EBITDA of ₹-65, an operating margin of -506.0% and a profit margin of 11740.0%.
Sun Pharma Advanced Research Co Share Price Chart
Track the current stock price of Sun Pharma Advanced Research Co with an interactive chart. Analyse SPARC share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sun Pharma Advanced Research Co stock quote in one place.
The quote of ₹191.26 sits between the 52-week low of ₹108.71 and the 52-week high of ₹277.57, and the latest session moved -1.48% from the previous close.
Sun Pharma Advanced Research Co Company Profile - Fundamental Screener
Screen Sun Pharma Advanced Research Co company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SPARC shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, with Dilip S Shanghvi listed as chairperson or CEO, and it trades under ISIN INE232I01014.
Business Overview
Sun Pharma Advanced Research Company Ltd. (SPARC) is an India-based clinical-stage biopharmaceutical company focused on developing new drugs and delivery systems. It specializes in creating therapeutics in oncology, neurology, and immunology. SPARC's key projects include vodobatinib for chronic myelogenous leukemia and neurodegenerative diseases, an anti-MUC-1 antibody-drug conjugate for multiple cancers,...more
Company Details
Classification
Identifiers and Leadership
Sun Pharma Advanced Research Co Balance Sheet Screener
Screen SPARC balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹2,171, up from ₹336 in 2025.
Latest statistics put total assets at ₹2,171 and shareholder funds at ₹1,339, with a leverage ratio of 0.74.
| Item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
Assets |
||||
| Total Assets | 2,171 | 336 | 515 | 830 |
| Current Assets | 1,862 | 26 | 269 | 455 |
| Fixed Assets | 85 | 99 | 108 | 106 |
Liabilities |
||||
| Total Liabilities | 0 | 0 | 0 | 0 |
| Current Liabilities | 78 | 178 | 124 | 138 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||
| Total Equity | 1,339 | -217 | 126 | 513 |
| Share Capital | 33 | 33 | 33 | 33 |
| Reserves & Surplus | 1,306 | -249 | 93 | 480 |
Sun Pharma Advanced Research Co Income Statement Screener - Profit & Revenue Analysis
Screen Sun Pharma Advanced Research Co income statement and profit fundamentals. Analyze SPARC quarterly results. Sun Pharma Advanced Research Co reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹15 and net profit was ₹1,761, equal to earnings per unit of ₹54.27, at an operating margin of -506%.
In that period expenses were ₹80, interest cost ₹12 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹64 and net profit of ₹-21.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | ||||||||||||||
| Revenue | 15 | 64 | 27 | 19 | 8 | 8 | 21 | 18 | 13 | 15 | 58 | 34 | 30 | 20 |
| Expenses | 80 | 74 | 80 | 62 | 74 | 77 | 122 | 110 | 116 | 89 | 137 | 126 | 113 | 117 |
Operating Costs and Margins | ||||||||||||||
| EBITDA | -65 | -10 | -53 | -43 | -66 | -69 | -101 | -92 | -103 | -74 | -79 | -92 | -83 | -96 |
| Operating Profit % | -506.00% | -85.00% | -196.00% | -540.00% | -836.00% | -817.00% | -639.00% | -555.00% | -800.00% | -494.00% | -188.00% | -427.00% | -432.00% | -740.00% |
| Depreciation | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest | 12 | 8 | 5 | 6 | 8 | 9 | 1 | 1 | 1 | 3 | 0 | 0 | 0 | 0 |
Profit and Earnings | ||||||||||||||
| Profit Before Tax | 1,761 | -21 | -61 | -52 | -76 | -80 | -105 | -96 | -107 | -79 | -82 | -95 | -86 | -100 |
| Tax | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1,761 | -21 | -60 | -52 | -76 | -80 | -106 | -96 | -107 | -80 | -82 | -95 | -86 | -100 |
| EPS | 54.27 | -0.64 | -1.84 | -1.60 | -2.34 | -2.48 | -3.26 | -2.96 | -3.31 | -2.45 | -2.55 | -2.94 | -2.66 | -3.07 |
Sun Pharma Advanced Research Co Cash Flow Screener - Liquidity Fundamentals
Screen SPARC cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹239, and net cash flow was an outflow of ₹1.
Over the same period, investing activities used ₹23 and financing activities provided ₹261.
| Item | 2026-March | 2025-March | 2024-March | 2023-March |
|---|---|---|---|---|
Cash from Operations and Investing | ||||
| Operating Activities | -239 | -360 | -429 | -69 |
| Investing Activities | -23 | 158 | 392 | -548 |
Financing and Net Cash | ||||
| Financing Activities | 261 | 199 | 42 | 617 |
| Net Cash Flow | -1 | -3 | 5 | -1 |
Sun Pharma Advanced Research Co Shareholding Pattern Screener
See Sun Pharma Advanced Research Co shareholding pattern with promoter, FII, and DII holdings. Check Sun Pharma Advanced Research Co promoter holding and ownership changes for SPARC on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 65.67%, foreign institutions 2.04%, domestic institutions 0.88% and the public 16.81%, spread across 140,625 shareholders.
The shareholder count was 140,625 in 2026-Mar, compared with 137,538 in 2026-May.
| Item | 2026-Mar | 2026-May | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% | 65.67% |
Institutional Investors | ||||||||
| FII Holding | 2.04% | 2.47% | 3.90% | 1.45% | 1.47% | 1.76% | 2.04% | 3.23% |
| DII Holding | 0.88% | 0.10% | 0.09% | 1.13% | 0.97% | 1.05% | 0.78% | 0.82% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 16.81% | 19.13% | 18.57% | 18.99% | 19.15% | 18.94% | 19.20% | 16.11% |
| Other Holding | 14.60% | 12.63% | 11.76% | 12.76% | 12.73% | 12.59% | 12.30% | 14.17% |
| Shareholder Count | 140,625 | 137,538 | 141,957 | 142,864 | 140,724 | 136,997 | 144,810 | 102,743 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sun Pharma Advanced Research Co. Sun Pharma Advanced Research Co dividend yield can be compared with peers and other stocks in the market.
Sun Pharma Advanced Research Co Stock Index Membership - Nifty & Sensex
See which indices include Sun Pharma Advanced Research Co stock. Check SPARC index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 9 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.
Complete Index List
Sun Pharma Advanced Research Co Market Events Screener - Corporate Actions
Get Sun Pharma Advanced Research Co corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sun Pharma Advanced Research Co stock events that may affect SPARC share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated August 10, 2026, with a record date of August 10, 2026.
It is followed by Annual General Meeting dated August 10, 2026 and Quarterly Result Announcement dated May 18, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-10 | 2026-08-10 | Quarterly Result Announcement | NA | 3.30% |
| 2026-08-10 | 2026-08-10 | Annual General Meeting | NA | -11.00% |
| 2026-05-18 | 2026-05-18 | Quarterly Result Announcement | NA | -5.35% |
| 2026-02-09 | 2026-02-09 | Extraordinary General Meeting | NA | 2.66% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 4.31% |
| 2025-11-10 | 2025-11-10 | Quarterly Result Announcement | NA | -2.74% |
| 2025-08-12 | 2025-08-12 | Annual General Meeting | NA | -9.42% |
| 2025-08-04 | 2025-08-04 | Quarterly Result Announcement | NA | -1.45% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 14.45% |
| 2025-02-10 | 2025-02-10 | Quarterly Result Announcement | NA | 0.79% |
| 2024-11-04 | 2024-11-04 | Quarterly Result Announcement | NA | 4.07% |
| 2024-08-12 | 2024-08-12 | Annual General Meeting | NA | -12.92% |
Sun Pharma Advanced Research Co Competitors Screener - Peer Stocks Comparison
Screen SPARC competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 440,998 | 36.70 | 61,674 | 12.69% | 11,565 | 40.74 |
| Divis Laboratories | 253,522 | 87.22 | 11,067 | 13.95% | 2,568 | 63.87 |
| Torrent Pharmaceuticals | 185,201 | 87.95 | 13,886 | 20.34% | 2,138 | 46.50 |
| Zydus Life Science | 122,257 | 26.11 | 27,658 | 17.64% | 5,026 | 66.57 |
| Cipla | 111,782 | 33.64 | 29,045 | 2.24% | 3,870 | 45.42 |
| Laurus Labs | 108,549 | 99.16 | 6,868 | 22.01% | 890 | 64.04 |
| Dr Reddys Laboratories | 101,913 | 31.54 | 35,059 | 3.90% | 4,158 | 63.11 |
| Mankind Pharma | 100,589 | 49.45 | 14,636 | 14.85% | 1,938 | 55.24 |
| Aurobindo Pharma | 97,670 | 26.54 | 34,145 | 5.56% | 3,503 | 54.66 |
| Lupin | 94,281 | 17.22 | 29,039 | 26.75% | 5,356 | 35.30 |
Sun Pharma Advanced Research Co Company Announcements - News & Reports Screener
Screen SPARC latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 2, 2026.
The next most recent announcements are dated August 13, 2026 and August 11, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-02 | Closure of Trading Window | - |
| 2026-08-13 | Filing Of Application For Reclassification With Stock Exchanges | - |
| 2026-08-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-10 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-10 | Announcement under Regulation 30 (LODR)-Monitoring Agency Report | - |
| 2026-08-10 | Unaudited Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-08-10 | Board Meeting Outcome for Outcome Of The Board Meeting | - |
| 2026-08-03 | Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2026 | - |
| 2026-07-27 | Intimation For Receipt Of Requests For Reclassification Of Shareholder Category | - |
| 2026-07-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-16 | Business Responsibility and Sustainability Reporting (BRSR) | - |
| 2026-07-16 | Notice Of 21St Annual General Meeting To Be Held On August 10 2026 Along With The Annual Report For FY 26 | - |
| 2026-07-16 | Reg. 34 (1) Annual Report. | - |
| 2026-07-13 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-07-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-07-06 | Intimation Regarding 21St Annual General Meeting Of The Company | - |
| 2026-07-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-26 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-06-25 | Termination Of License Agreement With CMS Bridging DMCC | - |
| 2026-06-24 | Closure of Trading Window | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹191.26, within a 52-week range of ₹108.71 to ₹277.57. The P/E ratio is 4.29 and the P/B ratio is 5.07, with earnings per unit of ₹47.86. Market capitalisation stands at ₹6,582.47 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 4 balance sheet periods, 14 income statement periods, 4 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.